Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Axios on your phone

Get breaking news and scoops on the go with the Axios app.

Download for free.

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Aïda Amer/Axios

An international collaboration of scientists announced Wednesday they have mapped out the cancer genome and also developed a new method of "carbon dating" cancer tumors to determine what and when mutations occurred that led to a person's cancer.

Why it matters: This meta-analysis of the whole genome is the first building block of a knowledge base that the scientists hope will help clinicians determine the precise treatment needed by individual patients — assuming the costs of sequencing and running algorithm programs continue to decline.

Background: Most previous research has focused on the 1% of the cancer genome, or the "exome," which provides instructions for protein coding. This sequencing often reveals one or more mutations — often called driver mutations — which are targetable in roughly two-thirds of patients.

  • But, as Wellcome Sanger Institute's Peter Campbell pointed out, clinicians are often amazed at how two patients with identical tumors would respond to treatments in opposite ways, showing "just how different one person’s cancer genome is from another's."
  • Campbell is a member of the steering committee for the Pan-Cancer Project, which is the decade-long collaboration of over 1,300 scientists and clinicians from 37 countries that helped produce these studies.

What they did: As published in 23 papers in Nature and its related journals, the teams analyzed more than 2,600 genomes of 38 different tumor types, including liver and breast cancer.

  • They created one of the largest resources of primary cancer genomes.
  • They also launched 16 working groups that studied different aspects of cancer's development, causation, progression and classification.

What they found: The researchers discovered they were able to identify about 95% of the tumor samples, and that many have four or five driver mutations that can be targeted. They did not find any drivers for about 5% of the cases.

  • Sequencing both the coding and non-coding portions of the genome allowed them to find many of the small changes that had impact and could be new drug targets, they said.
  • They also increased scientific understanding of the types of pathways involved in specific cancers that can help guide treatment options.

Plus, they developed a way to "carbon date" cancer, or identify mutations that had occurred many years ago that later played a role in cancer forming. From this method, they found about 20% of mutations actually occur years before tumor formation, and that half of these happen in the same nine genes.

  • "It's often years to a decade before they get all of the numbers of mutations required to become a full-grown cancer," Campbell said.
  • It's possible that diagnostics seeking these early mutations could help prevent cancer.

Of note: Two commentaries were published along with the studies.

  • The News & Views piece points out the ability to process hundreds of terabytes of data over millions of hours in multiple data centers was due to cloud computing, saying it's a "prime example of how cloud computing can make international collaboration possible and help to advance data-intensive fields."
  • The Comment piece says the time is now to develop an international code of conduct for data sharing to protect individual's privacy and ensure compliance with developing international laws.

The big picture: This is an important step toward the eventual goal of precise medicine — where a patient's tumor can be sequenced, and combined with consideration of lifestyle and other factors, find a comparable case to better advise treatment regime.

  • The costs of both sequencing and running algorithms need to continue dropping, but Campbell said he hopes "in a few years, this will be much more accessible than now and much more widely used."

Go deeper: Cancer death rates drop by largest amount on record in U.S.

Go deeper

36 mins ago - World

Putin denies Russia is behind cyberattacks ahead of Biden summit

In an exclusive interview with NBC's "Today," Russian President Vladimir Putin denied that Russia is waging cyber warfare against the United States and refused to guarantee opposition leader Alexei Navalny — whose name he would not say — will leave prison alive.

Why it matters: Cyberattacks by Russian intelligence and Russian-speaking criminal groups, as well as the Kremlin's attempted assassination and jailing of Navalny, are among the topics President Biden is expected to raise at his Geneva summit with Putin on Wednesday.

2 hours ago - Health

Novavax says COVID-19 vaccine was 90% effective in Phase 3 trial

Photo: Pavlo Gonchar/SOPA Images/LightRocket via Getty Images

Novavax, a Maryland biotechnology company, announced Monday that its COVID-19 vaccine was 90.4% effective in its Phase 3 trial, including against coronavirus variants.

Why it matters: The study of 29,960 participants in the U.S. and Mexico found the shot was safe and highly effective, paving the way for the FDA to clear a 4th vaccine for emergency use by the end of the year.